|Bid||135.14 x 1300|
|Ask||135.51 x 800|
|Day's Range||131.27 - 135.61|
|52 Week Range||102.96 - 149.07|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||29.24|
|Earnings Date||May 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||149.31|
Charles River Laboratories International, Inc. (CRL) will release first-quarter 2019 financial results on Tuesday, May 7th, before the market opens. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
Charles River Laboratories International Inc NYSE:CRLView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for CRL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CRL. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CRL are favorable with net inflows of $70.87 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Behind every patient stands thousands of scientists and researchers collaborating to develop life-saving drugs. Jenne’s story highlights the importance of that work.
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Charles River Laboratories International, Inc. (NYSE:CRL), which is in the life sciences business, and is based in United States, received a lot of attention from a substantial price increase onRead More...
The Zacks Analyst Blog Highlights: General Motors, Charles River, DSW, Shoe Carnival and Boingo
Charles River Laboratories International, Inc. announced today that it will present at two upcoming investor conferences, including:
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
CRL looks strong and probably capable of further gains but in the short-run we could see a pullback.